Fonte: Annals of Oncology. Nome do evento: Congress of European Society for Medical Oncology (ESMO). Unidade: FMRP
Assuntos: NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PERIA, Fernanda Maris et al. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis. Annals of Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1093/annonc/mdw387.29. Acesso em: 05 out. 2024. , 2016APA
Peria, F. M., Ungari, A. Q., Santos, F. N. D., Lins-Almeida, T., & Nunes, A. A. (2016). Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis. Annals of Oncology. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1093/annonc/mdw387.29NLM
Peria FM, Ungari AQ, Santos FND, Lins-Almeida T, Nunes AA. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis [Internet]. Annals of Oncology. 2016 ; 27[citado 2024 out. 05 ] Available from: https://doi.org/10.1093/annonc/mdw387.29Vancouver
Peria FM, Ungari AQ, Santos FND, Lins-Almeida T, Nunes AA. Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis [Internet]. Annals of Oncology. 2016 ; 27[citado 2024 out. 05 ] Available from: https://doi.org/10.1093/annonc/mdw387.29